AtriCure (ATRC) Competitors $34.63 -0.44 (-1.25%) Closing price 04:00 PM EasternExtended Trading$34.64 +0.01 (+0.03%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATRC vs. TFX, ITGR, ATEC, IART, OFIX, SRDX, ANGO, ARAY, RMTI, and RSLSShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry. AtriCure vs. Its Competitors Teleflex Integer Alphatec Integra LifeSciences Orthofix Medical Surmodics AngioDynamics Accuray Rockwell Medical ReShape Lifesciences AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Does the media favor ATRC or TFX? In the previous week, Teleflex had 3 more articles in the media than AtriCure. MarketBeat recorded 15 mentions for Teleflex and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.93 beat Teleflex's score of 0.67 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Teleflex 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in ATRC or TFX? 99.1% of AtriCure shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 3.5% of AtriCure shares are owned by company insiders. Comparatively, 1.4% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ATRC or TFX? Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtriCure$465.31M3.70-$44.70M-$0.77-44.97Teleflex$3.05B1.82$69.68M$4.2529.59 Is ATRC or TFX more profitable? Teleflex has a net margin of 6.31% compared to AtriCure's net margin of -7.27%. Teleflex's return on equity of 15.08% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets AtriCure-7.27% -4.20% -3.19% Teleflex 6.31%15.08%8.85% Which has more volatility & risk, ATRC or TFX? AtriCure has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Do analysts prefer ATRC or TFX? AtriCure presently has a consensus price target of $50.89, suggesting a potential upside of 46.95%. Teleflex has a consensus price target of $141.57, suggesting a potential upside of 12.58%. Given AtriCure's stronger consensus rating and higher probable upside, research analysts clearly believe AtriCure is more favorable than Teleflex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Teleflex 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAtriCure and Teleflex tied by winning 8 of the 16 factors compared between the two stocks. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$10.84B$5.79B$10.19BDividend YieldN/A1.88%5.73%4.61%P/E Ratio-44.9713.9156.1422.50Price / Sales3.7030.42538.28122.35Price / CashN/A25.0025.8129.91Price / Book3.663.4313.256.28Net Income-$44.70M$210.63M$3.29B$270.38M7 Day Performance-3.81%-0.87%0.47%2.70%1 Month Performance-2.31%1.65%4.60%5.99%1 Year Performance22.76%-11.60%73.42%25.94% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure2.5197 of 5 stars$34.63-1.3%$50.89+47.0%+24.3%$1.74B$465.31M-44.971,300News CoveragePositive NewsTFXTeleflex4.6084 of 5 stars$130.20-0.4%$141.57+8.7%-47.0%$5.78B$3.05B30.6414,100Analyst DowngradeITGRInteger3.9876 of 5 stars$106.01-0.9%$140.25+32.3%-19.9%$3.75B$1.72B46.7011,000Positive NewsATECAlphatec4.28 of 5 stars$16.34-0.4%$18.50+13.2%+173.0%$2.43B$611.56M-14.46700Positive NewsIARTIntegra LifeSciences3.8023 of 5 stars$15.68-1.9%$18.43+17.5%-13.8%$1.25B$1.61B-2.404,396Positive NewsOFIXOrthofix Medical3.4863 of 5 stars$14.70+1.0%$21.50+46.3%-11.0%$574.64M$799.49M-4.641,616Positive NewsSRDXSurmodics4.5504 of 5 stars$32.93+1.7%$43.00+30.6%-18.8%$462.96M$126.08M-26.77450Positive NewsANGOAngioDynamics4.1648 of 5 stars$10.90+1.6%$19.00+74.3%+39.4%$436M$292.50M-13.13760Positive NewsARAYAccuray4.7117 of 5 stars$1.55+2.6%$5.00+222.6%-28.3%$170.14M$458.51M-77.501,040Positive NewsAnalyst UpgradeRMTIRockwell Medical3.8875 of 5 stars$1.59-1.9%$4.00+151.6%-58.2%$55.78M$87.97M-26.50300News CoverageShort Interest ↑Gap UpRSLSReShape LifesciencesN/A$3.16-1.4%N/A-99.7%$8.49M$8.01M-0.0350Gap DownHigh Trading Volume Related Companies and Tools Related Companies TFX Competitors ITGR Competitors ATEC Competitors IART Competitors OFIX Competitors SRDX Competitors ANGO Competitors ARAY Competitors RMTI Competitors RSLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRC) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
